Shennon Biotechnologies
Shennon Biotechnologies is a pre-revenue, San Francisco-based biotech founded in 2021 that combines an ultrafast single-cell functional screening platform (TCELERATOR) with proprietary AI models (PINTA, SERIS) to discover novel immunotherapy targets and predict clinical safety for pharmaceutical and biotech partners developing cancer and autoimmune disease treatments.
- Company typePrivate
- Founded2021
- HeadquartersSan Francisco, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Shennon Biotechnologies does
Shennon Biotechnologies is a privately held, pre-revenue biotech company founded in 2021 and based in San Francisco that develops a proprietary single-cell functional immune profiling platform for immunotherapy drug discovery. The company's core technology stack is built around three named components: TCELERATORTM, an ultrafast functional screening platform that dynamically profiles tens of millions of single cell-cell interactions to identify rare disease-relevant populations; PINTATM, an AI engine that integrates multidimensional tumor and normal sample data to discover novel therapeutic targets for previously 'undruggable' diseases; and SERISTM, an AI model that analyzes normal human tissue molecular data to predict potential cross-reactivity and clinical toxicity of drug candidates. The company states that SERISTM has predicted 100% of previously reported toxicity events and that the combined platform can halve drug development timelines.
The company targets pharmaceutical and biotechnology companies developing immunotherapies for cancer (with emphasis on solid tumors) and autoimmune diseases, addressing pain points such as difficulty identifying rare disease-relevant cell populations, slow and costly target discovery, high clinical failure rates from unpredicted toxicities, and limited treatment options for 'undruggable' indications. Its go-to-market is a B2B enterprise motion executed through direct engagement with pharma partners, supported by a scientific advisory board that includes former senior R&D leaders from Eli Lilly, J&J, Bristol Myers Squibb, and Pfizer, and academic experts from Harvard, MSKCC, UCSF, Weill Cornell, and Fred Hutch.
Shennon's business model is structured around technology platform licensing and co-development partnerships with pharmaceutical companies, with expected revenue streams including upfront payments, research funding, milestone payments, and royalties; the company has not yet announced any signed commercial agreements and remains pre-revenue as of November 2025. The company has raised $13 million in a March 2023 seed round led by DCVC with participation from Foundation Capital, AV8 Ventures, angel investors, and several additional VC firms listed on the company website, and is actively hiring across immunology (T cell engager and TCR-T cell therapy programs) and machine learning research functions.
Shennon Biotechnologies firmographics
Firmographics- Name
- Shennon Biotechnologies
- Legal name
- Shennon Biotechnologies Inc.
- Website
- https://shennonbio.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Shennon Biotechnologies is a pre-revenue, San Francisco-based biotech founded in 2021 that combines an ultrafast single-cell functional screening platform (TCELERATOR) with proprietary AI models (PINTA, SERIS) to discover novel immunotherapy targets and predict clinical safety for pharmaceutical and biotech partners developing cancer and autoimmune disease treatments.
- Ownership category
- akta.pro rank
Shennon Biotechnologies industry classification
Industry- Product category
- Biotechnology Drug Discovery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro industry
- Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
Keywords
Where Shennon Biotechnologies is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Shennon Biotechnologies business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Technology Platform Licensing and Partnerships: Pre-revenue biotech company. Revenue model likely to include licensing of technology platform to pharmaceutical companies, co-development partnerships, and milestone-based payments from drug development collaborations. The company develops proprietary technology for immunotherapy target discovery that can be offered to pharma partners.
- Drug Discovery Co-development: Strategic co-development arrangements with pharmaceutical companies for specific therapeutic targets, potentially generating upfront payments, research funding, and downstream milestone and royalty payments.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Shennon Biotechnologies product offering
Product offeringCore offering
Shennon Biotechnologies develops a proprietary single-cell functional immune profiling platform that combines ultrafast high-throughput screening of tens of millions of cell-cell interactions with proprietary AI models to discover novel immunotherapy targets and predict clinical safety for cancer and autoimmune disease drug development. Its three named offerings — TCELERATORTM, PINTATM and SERISTM — together form a technology stack licensed or co-developed with pharmaceutical and biotechnology partners rather than sold as standalone off-the-shelf products.
Product overview
Shennon Biotechnologies operates as a unified platform company combining three core proprietary technologies. The TCELERATORTM platform provides ultrafast functional single-cell screening at tens of millions of events per run. PINTATM is an AI engine for novel target discovery from multidimensional tumor and normal sample datasets. SERISTM is an AI safety model for predicting clinical toxicity. Together, these technologies enable faster and safer immunotherapy development for cancer and autoimmune diseases.
Differentiator
Problem solved
Functional benefit
Brands
- TCELERATORTM: Proprietary platform that enables ultrafast functional and dynamic profiling of millions of single cell interactions to find rare populations and screen for immune modulating agents by specific function.
- PINTATM
- SERISTM
Products and services
- TCELERATORTM TCELERATORTM is a proprietary ultrafast functional screening platform that dynamically probes tens of millions of single cell-cell interactions, enabling high-throughput identification and characterization of rare cell populations and screening of therapeutic agents by specific function. It is offered to pharmaceutical and biotech companies developing immunotherapies for cancer and autoimmune diseases.
- PINTATM PINTATM is a proprietary AI engine that integrates multiple dimensions of data from a large set of tumor and normal samples to discover therapeutically relevant, novel targets for previously 'undruggable' diseases, providing a therapeutic path for patients with limited or no treatment options. It is offered to pharmaceutical and biotech partners developing immunotherapies.
- SERISTM SERISTM is an AI-driven deep molecular scanning model that analyzes molecular details of normal human tissues to look for potential cross-reactivity with drug candidates. It has reportedly predicted 100% of previously reported toxicity events, providing a safeguard for drug design. It is offered to pharmaceutical and biotech partners as a clinical safety prediction tool.
Quantifiable outcome
- Cuts drug development time in half while ensuring safety by predicting clinical failures
- +1 more outcomes
Companies that use Shennon Biotechnologies
Customer profileSegments1 record
Ideal customer profiles1 record
Shennon Biotechnologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
Shennon Biotechnologies partnerships and signals
Strategic signalScale indicators3 records
Recent moves5 records
Expansion highlights4 records
Shennon Biotechnologies competitors and assessment
Company assessmentDirect peers
- 10x Genomics: Public leader in single-cell genomics and immune profiling platforms (Chromium, Visium). Competes with Shennon's TCELERATOR™ on the single-cell analysis layer that pharma discovery teams use, though 10x focuses on genomic profiling rather than ultrafast functional cell-cell interaction screening.
- AbCellera Biologics: AI-enabled antibody discovery platform that partners with pharma to identify and develop therapeutic candidates from single B cells. Closely comparable to Shennon in applying single-cell + AI to immunotherapy target discovery and signing pharma licensing/co-development deals.
- Generate Biomedicines: AI/ML-driven biologics platform focused on computationally designing novel protein therapeutics. Directly comparable to Shennon's PINTA™/SERIS™ AI engine approach and its pharma partnership business model around differentiated biologic targets.
- Insitro: Machine-learning-driven drug discovery company partnering with pharma (e.g., Bristol Myers Squibb, Eli Lilly) for target identification and development. Comparable to Shennon in combining AI/ML with biological data to enable pharma partnerships and platform-licensing economics.
- Bruker Cellular Analysis (formerly Berkeley Lights): Single-cell functional screening platform using optofluidic technology to profile immune cells and antibodies. Directly overlaps with TCELERATOR™'s functional profiling of immune cell-cell interactions for immunotherapy discovery.
- Standard BioTools (formerly IsoPlexis): Single-cell functional immune profiling platform used by pharma for cell therapy and immunotherapy development. Comparable to Shennon in serving pharma with single-cell functional data for immunotherapy target identification.
Emerging players
- Adagene: Clinical-stage immunotherapy company using AI-driven antibody discovery (POWER platform) to develop novel therapeutics. Comparable in AI-enabled immunotherapy discovery focus and pharma partnership orientation, though more advanced in clinical pipeline.
- BioMap: AI/ML-driven protein engineering platform for therapeutic antibody and enzyme design. Notable comparable because Tek Hyung Lee, Shennon's Senior Scientist, previously worked at BioMap on TCE engineering — reflecting similar AI+bio approach to immuno-therapeutic design.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Shennon Biotechnologies social profiles
Digital presenceShennon Biotechnologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Shennon Biotechnologies leadership team
Management profileNumber of profiles
Profiles21 records
Shennon Biotechnologies funding detail
Funding detailFunding overview
Funding rounds2 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Shennon Biotechnologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Shennon Biotechnologies
What does Shennon Biotechnologies do?
Shennon Biotechnologies develops a proprietary single-cell functional immune profiling platform that combines ultrafast high-throughput screening of tens of millions of cell-cell interactions with proprietary AI models to discover novel immunotherapy targets and predict clinical safety for cancer and autoimmune disease drug development. Its three named offerings — TCELERATORTM, PINTATM and SERISTM — together form a technology stack licensed or co-developed with pharmaceutical and biotechnology partners rather than sold as standalone off-the-shelf products.
Is Shennon Biotechnologies a public or private company?
Shennon Biotechnologies is a private company. It is classified as venture growth investor backed and is currently operating.
When was Shennon Biotechnologies founded?
Shennon Biotechnologies was founded in 2021. It employs 11 to 50 people.
Where is Shennon Biotechnologies based?
Shennon Biotechnologies is headquartered in San Francisco, United States, in the North America region.
How does Shennon Biotechnologies make money?
Two revenue lines are on record. Technology Platform Licensing and Partnerships are the primary driver. The others are drug Discovery Co-development.
Who are Shennon Biotechnologies's main competitors?
Direct peers on record are 10x Genomics, AbCellera Biologics, Generate Biomedicines, Insitro, Bruker Cellular Analysis (formerly Berkeley Lights) and Standard BioTools (formerly IsoPlexis). Emerging players are Adagene and BioMap.
Does Shennon Biotechnologies have an API?
No public API is recorded for Shennon Biotechnologies.
What industry is Shennon Biotechnologies in?
Shennon Biotechnologies's product category is Biotechnology Drug Discovery Platform. Its primary akta.pro industry code is HLAAAIAF, Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.